TRIP13, identified as a hub gene of tumor progression, is the target of microRNA-4693-5p and a potential therapeutic target for colorectal cancer

• Published in: Cell death discovery 2022-01, Vol.8 (1), p.35-35, Article 35
• Main Authors: Chen, Yan, Chen, Danqi, Qin, Ying, Qiu, Cheng, Zhou, Yaoyao, Dai, Mengmeng, Li, Lulu, Sun, Qinsheng, Jiang, Yuyang
• Format: Article
• Language: English
• Subjects: 3' Untranslated regions; 631/67/1857; 631/67/395; Antitumor agents; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cancer; Cell Biology; Cell cycle; Cell Cycle Analysis; Cell migration; Cell proliferation; Colorectal cancer; Colorectal carcinoma; Gastrointestinal tract; Life Sciences; miRNA; mRNA; Stem Cells; Therapeutic targets; Thyroid; Tumor cell lines
• ISSN: 2058-7716; 2058-7716
• DOI: 10.1038/s41420-022-00824-w

Colorectal cancer (CRC) is one of the digestive tract malignancies whose early symptoms are not obvious. This study aimed to identify novel targets for CRC therapy, especially early-stage CRC, by reanalyzing the publicly available GEO and TCGA databases. Thyroid hormone receptor interactor 13 (TRIP13) correlated with tumor progression and prognosis of patients after several rounds of analysis, including weighted gene correlation network analysis (WGCNA), and further chosen for experimental validation in cancer cell lines and patient samples. We identified that mRNA and protein levels of TRIP13 increased in CRC cells and tumor tissues with tumor progression. miR-4693-5p was significantly downregulated in CRC tumor tissues and bound to the 3′ untranslated region (3′UTR) of TRIP13, downregulating TRIP13 expression. DCZ0415, a small molecule inhibitor targeting TRIP13, induced anti-tumor activity in vitro and in vivo. DCZ0415 markedly suppressed CRC cell proliferation, migration, and tumor growth, promoted cell apoptosis, and resulted in the arrest of the cell cycle. Our research suggests that TRIP13 might play a crucial role in CRC progression and could be a potential target for CRC therapy.